A continuing partnership between Australia and Germany to research men’s reproductive health
In May 2017, Germany’s peak research funding body, the DFG, announced it would renew funding of an International Research Training Group (IRTG) between Monash University and Justus-Liebig University (JLU), Germany. Dr Betty Exintaris from Drug Discover Biology has been involved in a project as part of the IRTG for the last three years. Dr Exintaris and Dr Mikey Whittaker have been successful in securing funding going forward for a new project regarding a novel target for the treatment of the lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).
As part of the renewed program 22 PhD students will have the opportunity to spend time at both Monash and JLU, working in a range of laboratories, including some within MIPS.
The primary objective of the IRTG, called Molecular Pathogenesis of Male Reproductive Disorders, is to train a new generation of researchers to tackle issues in men’s reproductive health. It focusses on innovative research to discover new therapies for the diagnosis and treatment of male infertility, testicular and prostate cancers and inflammatory disorders of the male reproductive tract.
This IRTG was first established in 2013 and will now be extended until 2022. The renewal funding will provide more than € 4.15 million (AUD$6.24 million) for the research partnership, with a further AUD$540,000 committed from Monash and the Faculty of Medicine Nursing and Health Sciences, along with 11 tuition and living stipend scholarships, to a total of $3,665,600.